source
- Immunotherapy startup Adecto shuts down, citing risk-averse funding climateAdecto Pharmaceuticals, a Boston-based immunotherapy biotech founded in 2014 by Tufts researchers, announced it is closing after 12 years. The company had been developing AD100, a monoclonal antib…
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…BioSpace · 19d ago↗ source
- Sanofi to pay $1 billion upfront to expand antibody partnership with Regeneron